[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute ...( ALISO VIEJO Calif. Oct. 2 /- Clar...)

ALISO VIEJO, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the company's CEO, Ronald Andrews, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.

The interview gives viewers an overview of the company, and the significance of the company's latest press release.

To view the clip in its entirety, visit:

http://www.tv.wallst.net/r/3-minute-press/Ron-Andrews-CLRT-ND/278/1108

Ask Ronald Andrews a question, post a comment on his personal page, and join his financial social network today at:

http://my.wallst.net/Ron-Andrews-CLRT-ND

About Clarient, Inc.:

Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care, and accelerate the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite a
'/>"/>